Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction

Biochemical and Biophysical Research Communications

Volumn 430, Issue 4, 2013, Pages 1234-1239

  Suwarti, Suwarti ^a   Yamazaki, Tomohiko ^a,b   Svetlana, Chechetka ^b   Hanagata, Nobutaka ^a,b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Extracellular domain; Immunostimulatory; Ligand binding sites; Oligodeoxynucleotide; Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HISTONE; INTERLEUKIN 6; PHOSPHODIESTERASE; PHOSPHOROTHIOIC ACID; TOLL LIKE RECEPTOR 9; TYROSINE;

AMINO TERMINAL SEQUENCE; ARTICLE; B LYMPHOCYTE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

CPG ISLANDS; CYTOKINES; HEK293 CELLS; HUMANS; MUTATION; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 84872835458     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.068     Document Type: Article

References (35)

1. Jin M.S., Lee J.-O. Structures of the Toll-like receptor family and its ligand complexes. Immunity 2008, 29:182-191.
2. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
3. Botos I., Segal D.M., Davies D.R. The structural biology of Toll-like receptors. Structure 2011, 19:447-459.
4. Wei T., Gong J., Rössle S.C., et al. A leucine-rich repeat assembly approach for homology modeling of the human TLR5-10 and mouse TLR11-13 ectodomains. J. Mol. Model. 2011, 17:27-36.
5. Ahmad-Nejad P., Häcker H., Rutz M., et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002, 32:1958-1968.
6. Verthelyi D., Ishii K.J., Gursel M., et al. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 2001, 166:2372-2377.
7. Jahrsdörfer B., Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Invest. Drugs 2003, 4:686-690.
8. Fonseca D.E., Kline J.N. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Delivery Rev. 2009, 61:256-262.
9. Klinman D.M., Klaschik S., Sato T., et al. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Delivery Rev. 2009, 61:248-255.
10. Matsushima N., Tanaka T., Enkhbayar P., et al. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genom. 2007, 8:124.
11. Barton G.M., Kagan J.C., Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 2006, 7:49-56.
12. Leifer C.A., Brooks J.C., Hoelzer K., et al. Cytoplasmic targeting motifs control localization of Toll-like Receptor 9. J. Biol. Chem. 2006, 281:35585-35592.
13. McKelvey K.J., Highton J., Hessian P.A. Cell-specific expression of TLR9 isoforms in inflammation. J. Autoimmun. 2011, 36:76-86.
14. Peter M.E., Kubarenko A.V., Weber A.N.R., et al. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J. Immunol. 2009, 182:7690-7697.
15. Kubarenko A.V., Ranjan S., Rautanen A., et al. A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness. J. Biol. Chem. 2010, 285:36486-36494.
16. Bartz H., Mendoza Y., Gebker M., et al. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes. Vaccine 2004, 23:148-155.
17. Roberts T.L., Sweet M.J., Hume D.A., et al. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J. Immunol. 2005, 174:605-608.
18. Li Y., Berke I.C., Modis Y. DNA binding to proteolytically activated TLR9 is sequence-independent and enhanced by DNA curvature. EMBO J. 2012, 31:919-931.
19. Wagner H. New vistas on TLR9 activation. Eur. J. Immunol. 2011, 41:2814-2816.
20. Meng W., Yamazaki T., Nishida Y., et al. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotech. 2011, 11:88.
21. Ewald S.E., Lee B.L., Lau L., et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
22. Park B., Brinkmann M.M., Spooner E., et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008, 9:1407-1414.
23. Wei T., Gong J., Jamitzky F., et al. Homology modeling of human Toll-like receptors TLR7, 8, and 9 ligand-binding domains. Protein Sci. 2009, 18:1684-1691.
24. Barrat F.J., Meeker T., Gregorio J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005, 202:1131-1139.
25. Haas T., Metzger J., Schmitz F., et al. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008, 28:315-323.
26. Hartmann G., Weeratna R.D., Ballas Z.K., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000, 164:1617-1624.
27. Sepulveda F.E., Maschalidi S., Colisson R., et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31:737-748.
28. Qi R., Singh D., Kao C.C. Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. J. Biol. Chem. 2012, 287:32617-32629.
29. Rutz M., Metzger J., Gellert T., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 2004, 34:2541-2550.
30. Kim D., Rhee J.W., Kwon S., et al. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem. Biophys. Res. Commun. 2009, 379:362-367.
31. Vollmer J., Rissini D.W., Marion J., et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004, 113:212-223.
32. Elias F., Flo J., Lopez R.A., et al. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J. Immunol. 2003, 171:3697-3704.
33. Zhao Q., Temsamani J., Iadarola P.L., et al. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 1996, 51:173-182.
34. Liang H., Nishioka Y., Reich C.F., et al. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 1996, 98:1119-1129.
35. Monteith D.K., Henry S.P., Howard R.B., et al. Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug. Des. 1997, 12:421-432.